Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02728388 · ClinicalTrials.gov registry record · Phase 2
Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II
A Phase 2 study of Neurofibromatosis 1, sponsored by Donald Basel.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT02728388 is a Phase 2 study of Neurofibromatosis 1 that is actively recruiting participants, run by Donald Basel. The registered enrollment target is 30 participants, below the 1,034-participant average among 24 other Neurofibromatosis 1 trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02728388, a Phase 2 study of Neurofibromatosis 1, is actively recruiting participants, sponsored by Donald Basel.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators wish to determine the time to disease progression for benign neurofibromas treated with Levulan Kerastick topical photosensitizer and red light photodynamic therapy (PDT) in patients with neurofibromatosis type 1 (NF1). The investigators also wish to measure tumor size for control and treatment tumors in order to gain insights into tumor growth rates.
Conditions Studied
Interventions
- DRUG aminolevulinic acid
Study Locations (1)
Wisconsin
- Donald G Basel - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-08 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02728388
The ClinicalTrials.gov registry entry for NCT02728388 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,034-participant average among 24 other Neurofibromatosis 1 trials with a reported enrollment target (97% lower). The listed sponsor is Donald Basel, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neurofibromatosis 1 appearing as the primary indexed condition, and to 1 intervention - of which aminolevulinic acid is the first listed.
NCT02728388 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT02728388 about?
NCT02728388 is a clinical study titled "Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II". The investigators wish to determine the time to disease progression for benign neurofibromas treated with Levulan Kerastick topical photosensitizer and red light photodynamic therapy (PDT) in patients with neurofibromatosis type 1 (NF1). The investigators also wish to measure tumor size for control...
What is the current status of trial NCT02728388?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2016-08. Estimated completion is 2025-12.
What conditions does trial NCT02728388 study?
This clinical trial studies the following conditions: Neurofibromatosis 1.
What interventions are being tested in trial NCT02728388?
The interventions under investigation include: aminolevulinic acid (DRUG).
Who is sponsoring clinical trial NCT02728388?
This trial is sponsored by Donald Basel, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02728388 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurofibromatosis 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1
RECRUITING · Phase 2
-
Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1
ACTIVE NOT RECRUITING · Phase 2
-
NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
COMPLETED · Phase 2
-
A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
RECRUITING · NA
-
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial
RECRUITING · NA
-
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.